SK156698A3 - Use of substituted azaspirane in the treatment of asthma - Google Patents
Use of substituted azaspirane in the treatment of asthma Download PDFInfo
- Publication number
- SK156698A3 SK156698A3 SK1566-98A SK156698A SK156698A3 SK 156698 A3 SK156698 A3 SK 156698A3 SK 156698 A SK156698 A SK 156698A SK 156698 A3 SK156698 A3 SK 156698A3
- Authority
- SK
- Slovakia
- Prior art keywords
- compound
- formula
- substituted
- carbon atoms
- pharmaceutically acceptable
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 16
- SERHTTSLBVGRBY-UHFFFAOYSA-N atiprimod Chemical class C1CC(CCC)(CCC)CCC11CN(CCCN(CC)CC)CC1 SERHTTSLBVGRBY-UHFFFAOYSA-N 0.000 title claims abstract description 7
- 241000124008 Mammalia Species 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 48
- 150000003839 salts Chemical class 0.000 claims description 18
- 239000012453 solvate Substances 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 5
- 241000282412 Homo Species 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000002327 eosinophilic effect Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 230000004941 influx Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000010445 mica Substances 0.000 description 3
- 229910052618 mica group Inorganic materials 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- WWCRKTZNNINNOT-SPIKMXEPSA-N (z)-but-2-enedioic acid;3-(8,8-dipropyl-2-azaspiro[4.5]decan-2-yl)-n,n-diethylpropan-1-amine Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C1CC(CCC)(CCC)CCC11CN(CCCN(CC)CC)CC1 WWCRKTZNNINNOT-SPIKMXEPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OVKXNUCFAMCUKG-UHFFFAOYSA-N C(C(O)CC(=O)O)(=O)O.C(C(O)CC(=O)O)(=O)O.C(C)N(CCCN1CC2(CC1)CCC(CC2)(CCC)CCC)CC Chemical compound C(C(O)CC(=O)O)(=O)O.C(C(O)CC(=O)O)(=O)O.C(C)N(CCCN1CC2(CC1)CCC(CC2)(CCC)CCC)CC OVKXNUCFAMCUKG-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MOUZYBYTICOTFQ-UHFFFAOYSA-N 3-(8,8-dipropyl-2-azaspiro[4.5]decan-2-yl)-n,n-diethylpropan-1-amine;hydron;dichloride Chemical compound Cl.Cl.C1CC(CCC)(CCC)CCC11CN(CCCN(CC)CC)CC1 MOUZYBYTICOTFQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- -1 N, N-dimethyl-8,8-dipropyl-2 -azaspiro [4,5] decane-2-propanamine dimalate Chemical compound 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1788996P | 1996-05-17 | 1996-05-17 | |
| PCT/IB1997/000688 WO1997044030A1 (en) | 1996-05-17 | 1997-05-15 | Use of substituted azaspirane in the treatment of asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK156698A3 true SK156698A3 (en) | 1999-06-11 |
Family
ID=21785110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1566-98A SK156698A3 (en) | 1996-05-17 | 1997-05-15 | Use of substituted azaspirane in the treatment of asthma |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6025364A (cs) |
| EP (1) | EP0910373A1 (cs) |
| JP (1) | JP2000513335A (cs) |
| KR (1) | KR20000010933A (cs) |
| CN (1) | CN1219129A (cs) |
| AU (1) | AU710542B2 (cs) |
| BR (1) | BR9709007A (cs) |
| CA (1) | CA2253217A1 (cs) |
| CZ (1) | CZ367598A3 (cs) |
| HU (1) | HUP0003908A3 (cs) |
| IL (1) | IL127040A0 (cs) |
| NO (1) | NO985325D0 (cs) |
| NZ (1) | NZ332627A (cs) |
| PL (1) | PL329931A1 (cs) |
| SK (1) | SK156698A3 (cs) |
| WO (1) | WO1997044030A1 (cs) |
| ZA (1) | ZA974271B (cs) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05009708A (es) * | 2003-03-10 | 2006-05-25 | Callisto Pharmaceuticals Inc | Metodo para el tratamiento de cancer con composiciones de azaspirina. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4963557A (en) * | 1987-09-28 | 1990-10-16 | Smithkline Beecham Corporation | Immunomodulatory azaspiranes |
| AU652583B2 (en) * | 1990-09-24 | 1994-09-01 | Smithkline Beecham Corporation | Methods |
| ZA921120B (en) * | 1991-02-19 | 1993-01-27 | Smithkline Beecham Corp | Cytokine inhibitors |
| US5482959A (en) * | 1992-01-28 | 1996-01-09 | Smithkline Beecham Corporation | Method for delaying aids in an HIV infected individual by administration of substituted azaspirane compounds |
| GB9315351D0 (en) * | 1993-07-23 | 1993-09-08 | Smithkline Beecham Corp | Methods |
| GB9315306D0 (en) * | 1993-07-23 | 1993-09-08 | Smithkline Beecham Corp | Methods |
| GB9315340D0 (en) * | 1993-07-23 | 1993-09-08 | Smithkline Beecham Corp | Methods |
-
1997
- 1997-05-15 EP EP97924183A patent/EP0910373A1/en not_active Withdrawn
- 1997-05-15 US US09/180,843 patent/US6025364A/en not_active Expired - Fee Related
- 1997-05-15 JP JP09541943A patent/JP2000513335A/ja active Pending
- 1997-05-15 SK SK1566-98A patent/SK156698A3/sk unknown
- 1997-05-15 CA CA002253217A patent/CA2253217A1/en not_active Abandoned
- 1997-05-15 HU HU0003908A patent/HUP0003908A3/hu unknown
- 1997-05-15 IL IL12704097A patent/IL127040A0/xx unknown
- 1997-05-15 AU AU29739/97A patent/AU710542B2/en not_active Ceased
- 1997-05-15 PL PL97329931A patent/PL329931A1/xx unknown
- 1997-05-15 NZ NZ332627A patent/NZ332627A/en unknown
- 1997-05-15 WO PCT/IB1997/000688 patent/WO1997044030A1/en not_active Application Discontinuation
- 1997-05-15 BR BR9709007-7A patent/BR9709007A/pt not_active Application Discontinuation
- 1997-05-15 KR KR1019980709081A patent/KR20000010933A/ko not_active Withdrawn
- 1997-05-15 CZ CZ983675A patent/CZ367598A3/cs unknown
- 1997-05-15 CN CN97194664A patent/CN1219129A/zh active Pending
- 1997-05-16 ZA ZA974271A patent/ZA974271B/xx unknown
-
1998
- 1998-11-16 NO NO985325A patent/NO985325D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL127040A0 (en) | 1999-09-22 |
| EP0910373A1 (en) | 1999-04-28 |
| HUP0003908A3 (en) | 2001-04-28 |
| WO1997044030A1 (en) | 1997-11-27 |
| KR20000010933A (ko) | 2000-02-25 |
| CA2253217A1 (en) | 1997-11-27 |
| ZA974271B (en) | 1998-08-25 |
| BR9709007A (pt) | 2000-01-04 |
| US6025364A (en) | 2000-02-15 |
| AU710542B2 (en) | 1999-09-23 |
| PL329931A1 (en) | 1999-04-26 |
| HUP0003908A2 (en) | 2001-03-28 |
| NO985325L (no) | 1998-11-16 |
| CN1219129A (zh) | 1999-06-09 |
| JP2000513335A (ja) | 2000-10-10 |
| NO985325D0 (no) | 1998-11-16 |
| NZ332627A (en) | 2001-06-29 |
| AU2973997A (en) | 1997-12-09 |
| CZ367598A3 (cs) | 1999-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK287972B6 (sk) | Pharmaceutical composition comprising 2-acetoxypyridine derivative and aspirin, kit comprising these compounds and use thereof | |
| US5057519A (en) | 5-HT3 antagonists: use in reducing opiate tolerance | |
| US5162341A (en) | Use of sigma receptor antagonists for treatment of amphetamine abuse | |
| JP2575569B2 (ja) | 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法 | |
| US4053617A (en) | 2,1,3-benzothiadiazoles as myolonolytics | |
| JPH02145518A (ja) | 偏頭痛の予防または治療用組成物 | |
| SK156698A3 (en) | Use of substituted azaspirane in the treatment of asthma | |
| US4617306A (en) | Pharmaceutical preparation comprising co-dergocrine and a calcium antagonist | |
| CA2119777C (en) | An ameliorant for blood lipid metabolism | |
| AU666175B2 (en) | A method for delaying HIV induced AIDS by administration of substituted azasperane compounds | |
| US5482959A (en) | Method for delaying aids in an HIV infected individual by administration of substituted azaspirane compounds | |
| SK11695A3 (en) | Use of 3-benzoyl-3,7-diazobicyclo£3,3,1| nonane compounds as antiarhytmic effective medicament and method of its production | |
| CZ227092A3 (en) | Pharmaceutical composition used in high blood pressure therapy | |
| AU7370894A (en) | Method of inhibiting the production of human immunodeficiency viruses with substituted azaspiranes | |
| US5786376A (en) | Methods of treating opportunistic infections with azaspiranes | |
| US4363809A (en) | Organic compounds | |
| US4145421A (en) | Treating spastic conditions | |
| AU7370994A (en) | Method of inhibiting the replication of human immunodeficiency viruses with substituted azaspiranes | |
| AU7514094A (en) | Methods of treating hiv with azaspiranes | |
| KR960005145B1 (ko) | 고혈압 및 울혈성 심부전증 치료용 약학적 조성물 | |
| MXPA98009596A (en) | Use of azaspiran substituted in the treatment of a | |
| AU684384B2 (en) | Method of treating opportunistic infections with azaspiranes | |
| HUT77381A (hu) | Eljárás növekedési hormonok hatásainak inhibiálására alkalmas benzotiofén-származékokat tartalmazó gyógyszerkészítmények előállítására |